509 related articles for article (PubMed ID: 32349208)
1. Pathogenic Roles of Autoantibodies and Aberrant Epigenetic Regulation of Immune and Connective Tissue Cells in the Tissue Fibrosis of Patients with Systemic Sclerosis.
Tsai CY; Hsieh SC; Wu TH; Li KJ; Shen CY; Liao HT; Wu CH; Kuo YM; Lu CS; Yu CL
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32349208
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis of scleroderma. Collagen.
Jimenez SA; Hitraya E; Varga J
Rheum Dis Clin North Am; 1996 Nov; 22(4):647-74. PubMed ID: 8923589
[TBL] [Abstract][Full Text] [Related]
3. Metabolic reprogramming of glycolysis and glutamine metabolism are key events in myofibroblast transition in systemic sclerosis pathogenesis.
Henderson J; Duffy L; Stratton R; Ford D; O'Reilly S
J Cell Mol Med; 2020 Dec; 24(23):14026-14038. PubMed ID: 33140521
[TBL] [Abstract][Full Text] [Related]
4. Intrinsic Deregulation of Vascular Smooth Muscle and Myofibroblast Differentiation in Mesenchymal Stromal Cells from Patients with Systemic Sclerosis.
Hegner B; Schaub T; Catar R; Kusch A; Wagner P; Essin K; Lange C; Riemekasten G; Dragun D
PLoS One; 2016; 11(4):e0153101. PubMed ID: 27054717
[TBL] [Abstract][Full Text] [Related]
5. Evolving insights into the cellular and molecular pathogenesis of fibrosis in systemic sclerosis.
Korman B
Transl Res; 2019 Jul; 209():77-89. PubMed ID: 30876809
[TBL] [Abstract][Full Text] [Related]
6. TGF-β-induced epigenetic deregulation of SOCS3 facilitates STAT3 signaling to promote fibrosis.
Dees C; Pötter S; Zhang Y; Bergmann C; Zhou X; Luber M; Wohlfahrt T; Karouzakis E; Ramming A; Gelse K; Yoshimura A; Jaenisch R; Distler O; Schett G; Distler JH
J Clin Invest; 2020 May; 130(5):2347-2363. PubMed ID: 31990678
[TBL] [Abstract][Full Text] [Related]
7. Long non-coding RNA HOTAIR drives EZH2-dependent myofibroblast activation in systemic sclerosis through miRNA 34a-dependent activation of NOTCH.
Wasson CW; Abignano G; Hermes H; Malaab M; Ross RL; Jimenez SA; Chang HY; Feghali-Bostwick CA; Del Galdo F
Ann Rheum Dis; 2020 Apr; 79(4):507-517. PubMed ID: 32041748
[TBL] [Abstract][Full Text] [Related]
8. Elevated Fibronectin Levels in Profibrotic CD14
Rudnik M; Hukara A; Kocherova I; Jordan S; Schniering J; Milleret V; Ehrbar M; Klingel K; Feghali-Bostwick C; Distler O; Błyszczuk P; Kania G
Front Immunol; 2021; 12():642891. PubMed ID: 34504485
[TBL] [Abstract][Full Text] [Related]
9. The Role of Pro-fibrotic Myofibroblasts in Systemic Sclerosis: From Origin to Therapeutic Targeting.
Romano E; Rosa I; Fioretto BS; Matucci-Cerinic M; Manetti M
Curr Mol Med; 2022; 22(3):209-239. PubMed ID: 33823766
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic factors as drivers of fibrosis in systemic sclerosis.
Bergmann C; Distler JH
Epigenomics; 2017 Apr; 9(4):463-477. PubMed ID: 28343418
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis.
Noda S; Asano Y; Nishimura S; Taniguchi T; Fujiu K; Manabe I; Nakamura K; Yamashita T; Saigusa R; Akamata K; Takahashi T; Ichimura Y; Toyama T; Tsuruta D; Trojanowska M; Nagai R; Sato S
Nat Commun; 2014 Dec; 5():5797. PubMed ID: 25504335
[TBL] [Abstract][Full Text] [Related]
12. Canonical Wnt signalling as a key regulator of fibrogenesis - implications for targeted therapies?
Dees C; Distler JH
Exp Dermatol; 2013 Nov; 22(11):710-3. PubMed ID: 24118232
[TBL] [Abstract][Full Text] [Related]
13. Pathophysiology of systemic sclerosis.
Thoreau B; Chaigne B; Renaud A; Mouthon L
Presse Med; 2021 Apr; 50(1):104087. PubMed ID: 34718115
[TBL] [Abstract][Full Text] [Related]
14. Sirt1 regulates canonical TGF-β signalling to control fibroblast activation and tissue fibrosis.
Zerr P; Palumbo-Zerr K; Huang J; Tomcik M; Sumova B; Distler O; Schett G; Distler JH
Ann Rheum Dis; 2016 Jan; 75(1):226-33. PubMed ID: 25180292
[TBL] [Abstract][Full Text] [Related]
15. Immune complexes containing scleroderma-specific autoantibodies induce a profibrotic and proinflammatory phenotype in skin fibroblasts.
Raschi E; Chighizola CB; Cesana L; Privitera D; Ingegnoli F; Mastaglio C; Meroni PL; Borghi MO
Arthritis Res Ther; 2018 Aug; 20(1):187. PubMed ID: 30157947
[TBL] [Abstract][Full Text] [Related]
16. An update on biomarker discovery and use in systemic sclerosis.
Matsushita T; Takehara K
Expert Rev Mol Diagn; 2017 Sep; 17(9):823-833. PubMed ID: 28730919
[TBL] [Abstract][Full Text] [Related]
17. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts.
Wang Y; Fan PS; Kahaleh B
Arthritis Rheum; 2006 Jul; 54(7):2271-9. PubMed ID: 16802366
[TBL] [Abstract][Full Text] [Related]
18. Methyl cap binding protein 2: a key epigenetic protein in systemic sclerosis.
Henderson J; Brown M; Horsburgh S; Duffy L; Wilkinson S; Worrell J; Stratton R; O'Reilly S
Rheumatology (Oxford); 2019 Mar; 58(3):527-535. PubMed ID: 30462328
[TBL] [Abstract][Full Text] [Related]
19. Current Concepts on the Pathogenesis of Systemic Sclerosis.
Truchetet ME; Brembilla NC; Chizzolini C
Clin Rev Allergy Immunol; 2023 Jun; 64(3):262-283. PubMed ID: 34487318
[TBL] [Abstract][Full Text] [Related]
20. A Human Skin Model Recapitulates Systemic Sclerosis Dermal Fibrosis and Identifies COL22A1 as a TGFβ Early Response Gene that Mediates Fibroblast to Myofibroblast Transition.
Watanabe T; Baker Frost DA; Mlakar L; Heywood J; da Silveira WA; Hardiman G; Feghali-Bostwick C
Genes (Basel); 2019 Jan; 10(2):. PubMed ID: 30678304
[No Abstract] [Full Text] [Related]
[Next] [New Search]
